PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Gisle Langslet et al.|The Lancet|2014Cited by 750
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialEvan A. Stein, Robert Pordy, Dan Gipe et al.|The Lancet|2012Cited by 579
Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial HypercholesterolemiaEvan A. Stein, Mary P. McGowan, Diane L. Tribble et al.|Circulation|2012Cited by 299